#haha777

#haha777 Walmart is rolling big TV deals for the holidays, and the sale price on this 75-Inch Hisense 4K UltraHD model is hard to pass up. The 75-Inch Hisense Class 4K UHD LED LCD Roku TV is now on sale for $478, instead of $698, for a savings of $220 off. This is big discount on a mega-sized 75-inch smart TV that has 4K UltraHD definition. This is 4 times the resolution of a traditional 1080P model with more pixels and a full-array LED backlight for brighter colors and greater detail. Featuring a Roku operating system, this 75-Inch Hisense 4K UltraHD Roku TV offers access to all your favorite streaming apps, live TV and more viewing content. It’s also voice compatible with Google Assistant or Alexa and has a gaming mode, motion rate 120 technology and Dolby Vision HDR and HDR10. Walmart is offering the big discount on this 75-Inch Hisense Roku TV with free next-day delivery. Shop for this 75-Inch Hisense 4K Roku TV deal at Walmart here. You can also check out more TVs on sale from Walmart , including these top offers: Find more holiday markdowns on smart TVs at Walmart here. The Best Deals in December Our journalism needs your support. Please subscribe today to NJ.com . Dawn Magyar can be reached at dmagyar@njadvancemedia.com . Have a tip? Tell us at nj.com/tips/ .La Salle defeats Temple 83-75

Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains

New Delhi, Nov 23 (PTI) India and the European Union (EU) have finalised an extensive roadmap for the green hydrogen sector that includes development of infrastructure, technology cooperation and boosting supply chains. The two sides deliberated on ways to enhance cooperation in the sector at the 10th meeting of the India-EU Energy Panel held on Thursday in Brussels. At the meeting, a "work plan" was adopted for the third phase of the India-EU Clean Energy and Climate Partnership 2025-28, which will focus on deeper cooperation in five priority areas, according to the Ministry of External Affairs (MEA). The priority areas are green hydrogen, offshore wind energy, regional connectivity, electricity market integration and smart grids, energy efficiency, and energy and climate diplomacy. "The two sides have set out an extensive agenda for green hydrogen cooperation, which includes assessing infrastructure development feasibility, regulatory and technology cooperation, and strengthening of supply chains," the MEA said on Saturday. It said the energy panel focused on the energy transition priorities of the two sides and took stock of the achievements of the second phase of the India-EU Clean Energy and Climate Partnership 2021-2024. The two sides undertook and completed joint initiatives involving technical cooperation in 51 activities divided into nine sectors, it added. "The two sides have also charted out the framework for green hydrogen cooperation, which includes cooperation on green hydrogen policies of India and the EU," the MEA said. The EU and EU member states participated in the international conference on green hydrogen this year in India. On its part, India joined as an exclusive country partner of European Hydrogen Week 2024. "India and the EU also entered into long-term research commitments to jointly support research in clean energy projects as part of the India-EU trade and technology council working group on clean and green technologies, which was established in January 2023," the MEA said. (This story has not been edited by THE WEEK and is auto-generated from PTI)SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR ® -SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002. "We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer's disease and remain committed in our mission to develop safe and effective treatments for the millions of people worldwide impacted by neurodegenerative diseases,” said Gary Romano, M.D., Ph.D., Chief Medical Officer at Alector. "With a robust dataset from the INVOKE-2 trial, we plan to further explore TREM2 biology. We extend our deepest gratitude to the dedicated investigators, patients and caregivers who made this important trial possible. We plan to share the results of the trial with the scientific community in the near future in the hopes of contributing to the understanding of AD pathophysiology and advancing effective therapeutics for this terrible disease.” Based upon the results, Alector is stopping the long-term extension study. Alector remains committed to advancing its mechanistically broad and genetically validated drug candidates for the treatment of neurodegenerative diseases. At the core of this effort are the company's progranulin-elevating programs, latozinemab and AL101/GSK4527226, developed in collaboration with GSK. Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a progranulin gene mutation is expected in late 2025 or early 2026. PROGRESS-AD, a global Phase 2 clinical trial evaluating AL101/GSK4527226 in early AD, has reached more than one-third of its target enrollment of 282 participants. Alector is also advancing its preclinical candidates aimed at a broad and diverse range of protein and enzyme targets. In addition to advancing its pipeline, the company is continuing to develop its proprietary and versatile blood-brain barrier technology platform, Alector Brain Carrier (ABC). ABC aims to enhance the delivery of therapeutic antibodies, proteins and enzymes, achieve deeper penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. To align resources with these strategic priorities, Alector is reducing its workforce by approximately 17%. By focusing on organizational goals, Alector continues to build upon its core strength in developing novel therapies for neurodegenerative diseases, with the potential to deliver transformative value for patients. As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call. About INVOKE-2 INVOKE-2 (Clinicaltrials.gov identifier NCT04592874), was a randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). The trial, conducted at multiple sites across 11 countries, utilized a common close design with up to 96 weeks of randomized treatment, and all participants remained on their assigned regimen until the last participant completed 48 weeks of treatment. This design provided the opportunity to capture more observations for the primary analysis, with data collected at 48, 72, and 96 weeks. Patients were randomized to three dose regimens of AL002, 15mg/kg IV/q4w, 40mg/kg IV/q4w, 60mg/kg IV/q4w, or placebo. About Alector Alector is a clinical-stage biotechnology company that has pioneered immuno-neurology. The company has discovered and is developing a portfolio of mechanistically broad and genetically validated product candidates, including antibodies, protein and enzyme replacement therapies, for neurodegenerative diseases. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Alector is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, workforce reduction, business strategy, product candidates, planned and ongoing preclinical studies and clinical trials, expected milestones, and expectations of our collaborations. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Quarterly Report on Form 10-Q filed on November 6, 2024, with the Securities and Exchange Commission ("SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law. Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected] 1AB (media) Dan Budwick 973-271-6085 [email protected] Argot Partners (investors) Laura Perry 212-600-1902 [email protected]

Via Vidarbha, road to power; perhaps CM chair too

Need proof Bake Off has gone stale? Look at the 2024 finalNone

Sporting Lisbon fans cause chaos with fireworks during Arsenal clash in Champions League - as they explode over David Raya's penalty areaIncarnate Word beats East Texas A&M 38-24 to finish undefeated in conference play

Burris 1-4 2-2 4, Koehler 3-11 0-0 6, Tew 1-3 0-0 2, Threatt 7-17 7-9 21, Tomley 7-12 8-8 28, Vucinic 1-4 0-0 2, Vartiainen 1-5 0-0 3, Hennig 1-2 0-0 2, Moore 0-0 0-0 0, Cutler 0-0 0-0 0. Totals 22-58 17-19 68. Coulibaly 6-10 5-9 17, Todorovic 5-12 2-2 13, Bethea 4-9 1-5 12, Odum 1-8 2-2 4, Butka 1-1 1-2 3, Dozic 0-4 4-4 4, Au-Duke 0-2 0-0 0, Mager 0-3 0-0 0, Olvera 0-2 0-0 0, Faure 0-1 0-0 0. Totals 17-52 15-24 53. Halftime_Weber St. 33-23. 3-Point Goals_Weber St. 7-24 (Tomley 6-7, Vartiainen 1-3, Burris 0-1, Hennig 0-1, Vucinic 0-1, Threatt 0-3, Koehler 0-8), Pepperdine 4-14 (Bethea 3-6, Todorovic 1-4, Odum 0-4). Rebounds_Weber St. 38 (Koehler 9), Pepperdine 35 (Coulibaly 11). Assists_Weber St. 8 (Threatt 4), Pepperdine 10 (Odum 7). Total Fouls_Weber St. 21, Pepperdine 17. A_924 (5,000).

Bill Dennis's outburst just latest episode in ongoing friction with city staff and councilSocial Security COLA 2025: Check Rates, Adjusted Amount, Payment Dates And More

A 7-year-old rivalry between tech leaders Elon Musk and Sam Altman over who should run OpenAI and prevent an artificial intelligence "dictatorship" is now heading to a federal judge as Musk seeks to halt the ChatGPT maker's ongoing shift into a for-profit company. Musk, an early OpenAI investor and board member, sued the artificial intelligence company earlier this year alleging it had betrayed its founding aims as a nonprofit research lab benefiting the public good rather than pursuing profits. Musk has since escalated the dispute, adding new claims and asking for a court order that would stop OpenAI’s plans to convert itself into a for-profit business more fully. The world's richest man, whose companies include Tesla, SpaceX and social media platform X, last year started his own rival AI company, xAI. Musk says it faces unfair competition from OpenAI and its close business partner Microsoft, which has supplied the huge computing resources needed to build AI systems such as ChatGPT. “OpenAI and Microsoft together exploiting Musk’s donations so they can build a for-profit monopoly, one now specifically targeting xAI, is just too much,” says Musk's filing that alleges the companies are violating the terms of Musk’s foundational contributions to the charity. OpenAI is filing a response Friday opposing Musk’s requested order, saying it would cripple OpenAI’s business and mission to the advantage of Musk and his own AI company. A hearing is set for January before U.S. District Judge Yvonne Gonzalez Rogers in Oakland. At the heart of the dispute is a 2017 internal power struggle at the fledgling startup that led to Altman becoming OpenAI's CEO. Musk also sought to be CEO and in an email outlined a plan where he would “unequivocally have initial control of the company” but said that would be temporary. He grew frustrated after two other OpenAI co-founders said he would hold too much power as a major shareholder and chief executive if the startup succeeded in its goal to achieve better-than-human AI known as artificial general intelligence , or AGI. Musk has long voiced concerns about how advanced forms of AI could threaten humanity. “The current structure provides you with a path where you end up with unilateral absolute control over the AGI," said a 2017 email to Musk from co-founders Ilya Sutskever and Greg Brockman. “You stated that you don't want to control the final AGI, but during this negotiation, you've shown to us that absolute control is extremely important to you.” In the same email, titled “Honest Thoughts,” Sutskever and Brockman also voiced concerns about Altman's desire to be CEO and whether he was motivated by “political goals.” Altman eventually succeeded in becoming CEO, and has remained so except for a period last year when he was fired and then reinstated days later after the board that ousted him was replaced. OpenAI published the messages Friday in a blog post meant to show its side of the story, particularly Musk's early support for the idea of making OpenAI a for-profit business so it could raise money for the hardware and computer power that AI needs. It was Musk, through his wealth manager Jared Birchall, who first registered “Open Artificial Technologies Technologies, Inc.”, a public benefit corporation, in September 2017. Then came the “Honest Thoughts” email that Musk described as the “final straw.” “Either go do something on your own or continue with OpenAI as a nonprofit,” Musk wrote back. OpenAI said Musk later proposed merging the startup into Tesla before resigning as the co-chair of OpenAI's board in early 2018. Musk didn't immediately respond to emailed requests for comment sent to his companies Friday. Asked about his frayed relationship with Musk at a New York Times conference last week, Altman said he felt “tremendously sad” but also characterized Musk’s legal fight as one about business competition. “He’s a competitor and we’re doing well,” Altman said. He also said at the conference that he is “not that worried” about the Tesla CEO’s influence with President-elect Donald Trump. OpenAI said Friday that Altman plans to make a $1 million personal donation to Trump’s inauguration fund, joining a number of tech companies and executives who are working to improve their relationships with the incoming administration. —————————— The Associated Press and OpenAI have a licensing and technology agreement allowing OpenAI access to part of the AP’s text archives.An average of 140 women and girls were killed by a partner or relative per day in 2023, the UN says

Investors should buy the postelection dip in renewable energy stocks, UBS says. The analysts point to a relatively cheap entry point and surging power demand from AI data centers. Renewables have slumped as investors expect Trump to scale back clean-energy initiatives. The recent sell-off in renewable energy stocks might be an opportunity to get in cheap, analysts at UBS said this week. They wrote in a note on Thursday that US and EU renewables have jumped to their top-ranking stock theme in recent weeks after the sector saw steep losses in the wake of Donald Trump 's election win. Now, with a cheap point of entry and huge and growing demand for power, it might be time to jump into the space, the analysts said. "The environment of an unrelenting power demand shock puts just about every source of power generation in a solid position to capitalize. Against a backdrop where positioning was not overweight, it seems the sentiment-driven downdraft presents an attractive entry point," the analysts said in a Wednesday note. The analysts said their optimism about surging power demand comes from rapid growth in AI and data center buildouts to power the technology. Data centers need a huge amount of power to operate, and their electricity demand is set to exceed supply in just two years, according to a recent estimate from Bernstein Research. The analysts suggested that data centers' outsized power needs mean they will likely need energy from all available sourcs, including renewables. "The rapid growth in AI and the subsequent Data Center buildout have resulted in an unrelenting demand for increased power generation. This, combined with continued emphasis on the importance of low-carbon solutions from Hyperscalers should pave the way for continued growth in Renewables," they said. The analysts' call comes as Trump's win has sent clean energy shares tumbling, even as much of the rest of the market has surged on the promise of lower taxes and less regulation. Stocks like Plug Power and Enphase Energy have shed over 24% since the election, while SolarEdge Technologies has plunged 42%. The President-elect, who said he wants to "drill baby, drill," is expected to scale back many of the Biden administration's clean-energy initiatives, including billions of dollars in solar and wind subsidies that were part of the Inflation Reduction Act. But the analysts said that investors' worst fears about the sector likely won't be realized. Companies using Biden-era subsidies could "grandfather" in support at the start of construction rather than risk losing it during a project, and states will likely continue to aim for lower emissions, they say. "We think that the concerns are overdone. In the view of our US utilities analyst, growth in renewables is likely to continue (solar installs were +50% in Trump's last term, compared to the previous 4 years) driven by state and corporate emission goals," the analysts said. Within the sector, the analysts said names poised for gains include US renewables stocks like NextEra and Generac, plus European stocks like Iberdrola, Siemens Energy, EDP, and developers like Ørsted and RWE.LAS VEGAS (AP) — A team that previously boycotted at least one match against the San Jose State women's volleyball program will again be faced with the decision whether to play the school , this time in the Mountain West Conference semifinals with a shot at the NCAA Tournament on the line. Five schools forfeited matches in the regular season against San Jose State, which carried a No. 2 seed into the conference tournament in Las Vegas. Among those schools: No. 3 Utah State and No. 6 Boise State, who will face off Wednesday with the winner scheduled to play the Spartans in the semifinals on Friday. Wyoming, Nevada and Southern Utah — which is not a Mountain West member — also canceled regular-season matches, all without explicitly saying why they were forfeiting. Nevada players cited fairness in women’s sports as a reason to boycott their match, while political figures from Wyoming, Idaho, Utah and Nevada suggested the cancellations center around protecting women’s sports. In a lawsuit filed against the NCAA , plaintiffs cited unspecified reports asserting there was a transgender player on the San Jose State volleyball team, even naming her. While some media have reported those and other details, neither San Jose State nor the forfeiting teams have confirmed the school has a trans women’s volleyball player. The Associated Press is withholding the player’s name because she has not publicly commented on her gender identity and through school officials has declined an interview request. A judge on Monday rejected a request made by nine current conference players to block the San Jose State player from competing in the tournament on grounds that she is transgender. That ruling was upheld Tuesday by an appeals court. “The team looks forward to starting Mountain West Conference tournament competition on Friday,” San Jose State said in a statement issued after the appeals court decision. “The university maintains an unwavering commitment to the participation, safety and privacy of all students at San Jose State and ensuring they are able to compete in an inclusive, fair and respectful environment.” Chris Kutz, a Boise State athletics spokesman, said in an email the university would not “comment on potential matchups at this time.” Doug Hoffman, an Aggies athletics spokesman, said in an email Utah State is reviewing the court’s order. “Right now, our women’s volleyball program is focused on the game this Wednesday, and we’ll be cheering them on,” Hoffman wrote. San Jose State, which had a first-round bye, would be sent directly to the conference title game if Utah State or Boise State were to forfeit again. If the Spartans make the title game, it's likely the opponent would not forfeit. They would face top-seeded Colorado State, No. 4 Fresno State or No. 5 San Diego State — all teams that played the Spartans this season. The conference champion receives an automatic bid to the NCAA Tournament. AP college sports: https://apnews.com/hub/college-sports

NRL Don't miss out on the headlines from NRL. Followed categories will be added to My News. The Broncos are in the box seat to sign Ben Hunt with the Queensland Origin star set to rule out a move to expansion rivals the Dolphins as D-Day approaches. This masthead can reveal the battle for Hunt’s signature has taken a dramatic twist, with a rumoured move to the Roosters in danger of collapsing, while Bulldogs football boss Phil Gould is poised to make a last-ditch pitch. That has sensationally opened the door for an ambush from the Broncos, who have been proactively courting Hunt in their push to engineer a Red Hill reunion. Hunt’s initial preference was to remain in Sydney for family reasons in the wake of his departure from the Dragons - leaving the Roosters and Bulldogs as serious options. But well-placed sources say Hunt is now leaning towards the Broncos after a tour of Brisbane’s opulent $27 million training headquarters, where he held preliminary talks with coach Michael Maguire and CEO Dave Donaghy. Ben Hunt last played for the Kangaroos in the Pacific Cup. Picture: Max Mason-Hubers Hunt also met with Brisbane’s River City rivals the Dolphins during his Sunshine State sortie, but it’s understood the 34-year-old has little interest in a move to Redcliffe. Hunt left Brisbane at the end of 2017, just as the club’s new training headquarters was being finalised, and he returned home last weekend to be blown away by the unrivalled infrastructure of the Broncos. The Australian utility still owns property in Brisbane and during last year’s Origin series, Hunt spoke of his desire to come home to Queensland. The Roosters were rated the frontrunner to win Hunt’s signature, but it’s understood the Bondi glamour club has salary-cap constraints and may not be able to win a bidding war. Hunt has run his eye over the individual rosters of his suitors - Brisbane, the Roosters, Dolphins and Bulldogs - and believes the Broncos are a ready-made force to help him achieve his final frontier: winning a premiership. It’s believed no club has tabled a formal deal for Hunt at this stage, but he hopes to garner all offers over the weekend with a view to making a definitive call early next week. Ben Hunt played 187 games for the Brisbane Broncos. Picture: Getty Images Canterbury supremo Gould shapes as the X-factor in Brisbane’s attempted raid. The Bulldogs have largely kept their powder dry, watching the Hunt machinations with interest, but after missing out on Storm superstar Ryan Papenhuyzen, Gould may up the ante in a bid to bring some playmaking experience to Belmore. Canterbury have set a budget of around $550,000 if they made an official move for Hunt and that figure may not be enough to secure the 334-game veteran. Hunt’s Dragons deal was worth $950,000 and the Dolphins are the only club with the salary-cap space to be able to offer a similar deal, but Redcliffe are currently a distant last in the race. One advantage for the Broncos is Hunt’s history with the club - he made his debut for Brisbane in 2009 and has unfinished business after the heartbreak of his 2015 grand-final loss to the Cowboys. Now, almost a decade later, Hunt is desperate to win a maiden premiership ring in his twilight years and Maguire said last week the Maroons maestro can help break Brisbane’s 19-year title drought in 2025. More Coverage Five factors that could swing Broncos into Hunt favouritism Peter Badel Maguire counts on unfinished business to bring Hunt home Peter Badel and Travis Meyn Originally published as Brisbane Broncos and Canterbury Bulldogs last clubs standing in battle for Ben Hunt Join the conversation Add your comment to this story To join the conversation, please log in. Don't have an account? Register Join the conversation, you are commenting as Logout More related stories NRL NRL’s huge step towards locking in 18th team The NRL could soon officially announce the competition’s 18th team after a huge update in their expansion push came to light. Read more NRL Jarryd Hayne, Ben Barba make rugby league comebacks Two former Dally M medallists, Jarryd Hayne and Ben Barba are set to play in a rugby league carnival on the Gold Coast. See the details here. Read more